New drug takes aim at Hard-to-Treat cancers

NCT ID NCT07046923

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 35 times

Summary

This study tests a new drug called LY4175408 for people with advanced lung, endometrial, or triple-negative breast cancer that has spread. The drug is designed to find and attack cancer cells carrying a specific marker (PTK7). The main goals are to check the drug's safety and see if it can shrink tumors. About 240 participants will take part, and the study lasts up to 4 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Institute Hospital of JFCR
RECRUITING

Tokyo, 135-8550, Japan
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Columbia University
RECRUITING

New York, New York, 10032, United States
Community Health Network
NOT_YET_RECRUITING

Indianapolis, Indiana, 46250, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute
RECRUITING

Orlando, Florida, 32827, United States
Florida Cancer Specialists - Sarasota
RECRUITING

Sarasota, Florida, 34236, United States
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
John Theurer Cancer Center At Hackensack UMC
RECRUITING

Hackensack, New Jersey, 07601, United States
Kyoto University Hospital
RECRUITING

Kyoto, 606-8507, Japan
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
National Cancer Center Hospital
RECRUITING

Tokyo, 104-0045, Japan
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Shanghai East Hospital, Tongji University
NOT_YET_RECRUITING

Shanghai, 0200120, China
Stanford Medicine Cancer Center
RECRUITING

Stanford, California, 94305, United States
The Ohio State University (OSU) Wexner Medical Center
RECRUITING

Columbus, Ohio, 43210, United States
The University of Chicago Medical Center (UCMC)
RECRUITING

Chicago, Illinois, 60637, United States
Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology
NOT_YET_RECRUITING

Wuhan, 430030, China
Washington University
RECRUITING

St Louis, Missouri, 63110, United States
West China Hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, 610041, China

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG ENDOMETRIAL NEOPLASMS ENDOMETRIAL NEOPLASMS NEOPLASM METASTASIS SMALL CELL LUNG CARCINOMA TRIPLE NEGATIVE BREAST CANCER